



NutriBand Inc. (NTRBW)


Nasdaq; healthcare; SIC 3842, Orthopedic, Prosthetic & Surgical Appliances & Supplies; CIK 0001676047

NutriBand Inc. NTRBW; healthcare					
Grade	D	 fourth fifth of 371 graded peers percentile 75.0; sampling error 2.5 points; lower is stronger			
Rank	278 of 371				
Profitability	C	 percentile 52.8			
Solvency	C	 percentile 49.8			
Growth and financing	D	 percentile 68.8			
Reliability	0.76 AUC filers with under \$12.5M assets; 95% interval 0.65 to 0.86; 63 events, 2020 to 2025				
Peer failure rate	0.60% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025				
Size band	under \$12.5M assets total assets \$7.5M				
Standard universe	outside revenue above \$1M and assets above \$10M				
Warnings	none active; fortress balance sheet not computable: dilution, distress				
Inputs computable	7 of 14				
Graded from	filings received through May 18, 2026 144 days before the rescans; latest periodic filing 10-Q received Sep 4, 2026				
Last close	\$0.92 2026-09-30; market equity \$0				
Price used in grade	None				



D, the sloth
fourth fifth of its sector; letters are fifths of the 371 graded peers

Share price, twelve months to the rescans
split-adjusted close; the letter is fixed at the rescans that set it



Rescans on file: B from May 21, 2023, D/E from May 21, 2024, C/D from May 21, 2025

Letter at every rescan

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



Business, in the company's words

opening of Item 1 of the 10-K received Apr 29, 2026

"we" or "us"), was incorporated in Nevada in January 2016. Our primary business is the development of a portfolio of transdermal pharmaceutical products. Our development pipeline primarily consists of transdermal products that are based on our proprietary AVERSA? abuse deterrent transdermal technology that we believe can be incorporated into existing transdermal patches that contain drugs that are susceptible to abuse and misuse such as opioid and stimulant drugs. services through our subsidiaries Pocono

Pharmaceuticals operating as Active Intelligence and 4P Therapeutics.

The fourteen inputs


lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 52.8						
Gross profitability		7.5%	32.2%	79.4	372	2026-01-31
Return on invested capital		not computable	9.3%			one or more required annual facts are missing
Accruals ratio		(41.2%)	(6.6%)	10.6	811	2026-01-31
Gross margin stability, five years		4.6 pts	2.8 pts	68.4	243	2026-01-31
Solvency, sleeve percentile 49.8						
Twelve-month failure probability		not computable	0.07%			firm-wide XBRL shares cannot be assigned to one ticker class
Altman Z double-prime		(15.84)	(0.31)	70.5	756	2026-01-31
Net debt to EBITDA		not computable	1.82x			required facts have no common fiscal period end interest
Interest coverage		not computable	(4.51x)			expense must exceed \$100,000
Current ratio		6.36x	2.96x	29.1	839	2026-01-31
Growth and financing, sleeve percentile 68.8						
Revenue growth, three-year compound		(0.7%)	10.0%	72.6	415	2026-01-31
Free cash flow growth, three-year compound		not computable	10.9%			current FCF must be positive and base FCF must exceed \$100,000
Reinvestment rate		not computable	37.1%			one or more required annual facts are missing
Asset growth, three years		(7.2%)	2.1%	65.1	704	2026-01-31
Net share issuance, one year		not computable	2.5%			firm-wide XBRL shares cannot be assigned to one ticker class

Warnings

1 of 7 checks triggered; none of them enters the letter

Check	Measured
Fortress balance sheet	cash minus debt is 25,543 USD; Altman Z is not used



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
274	Vir Biotechnology, Inc. (VIR)	73.8	D	
275	Viatis Inc. (VTRS)	74.1	D	
276	Precision Optics Corporation, Inc. (POCI)	74.3	D	dilution, fortress balance sheet
277	Retractable Technologies Inc. (RVP)	74.6	D	fortress balance sheet
278	NutriBand Inc. (NTRB)	75.0	D	fortress balance sheet
279	NutriBand Inc. (NTRBW) <	75.0	D	fortress balance sheet
280	Teleflex Inc. (TFX)	75.4	D	
281	Standard Biotoools Inc. (LAB)	75.7	D	late filer, fortress balance sheet
282	Abeona Therapeutics Inc. (ABEO)	75.9	D	fortress balance sheet
283	Cytosorbents Corp. (CTSO)	76.2	D	short runway, fortress balance sheet
284	Tilray Brands, Inc. (TLRY)	76.5	D	fortress balance sheet

What the price implies

at the 2026-09-30 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(73.5%)	8.0%	5
Distance from 52-week high	(79.0%)	(31.4%)	8
EBIT to enterprise value	not computable	(1.5%)	
Free cash flow yield	not computable	(1.0%)	
Book value to price	not computable	0.28	
Sales to price	not computable	0.31	
Composite equity issuance, five years	not computable	20.3%	
Relative strength against the sector, log excess return	(1.54)	(0.14)	5

Diagnostics

not in the grade

Measure	Value
Piotroski F-score None of 9, period end 2026-01-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	pass

Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	\$3.4M
Operating cash flow, four quarters	-\$3.6M
Months of runway	11.3
Days since last periodic filing	35 (10-Q received Sep 4, 2026)
Median daily dollar volume, 63 sessions	\$350

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	\$566,308	2026-01-31	2026-04-29	10-K	0001213900-26-049399
2	assets	us-gaap:Assets	\$7.5M	2026-01-31	2026-04-29	10-K	0001213900-26-049399
3	net income	us-gaap:NetIncomeLoss	-\$8.2M	2026-01-31	2026-04-29	10-K	0001213900-26-049399
4	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$5.1M	2026-01-31	2026-04-29	10-K	0001213900-26-049399
5	assets	us-gaap:Assets	\$7.5M	2025-01-31	2026-04-29	10-K	0001213900-26-049399
6	revenue	us-gaap:Revenues	\$2.0M	2026-01-31	2026-04-29	10-K	0001213900-26-049399
7	gross profit	us-gaap:GrossProfit	\$743,317	2025-01-31	2026-04-29	10-K	0001213900-26-049399
8	revenue	us-gaap:Revenues	\$2.1M	2025-01-31	2026-04-29	10-K	0001213900-26-049399
9	revenue	us-gaap:Revenues	\$2.1M	2024-01-31	2025-04-28	10-K	0001213900-25-036201
10	cost of revenue	us-gaap:CostOfRevenue	\$1.2M	2024-01-31	2025-04-28	10-K	0001213900-25-036201
11	gross profit	us-gaap:GrossProfit	\$750,404	2023-01-31	2023-04-26	10-K	0001213900-23-032682
12	revenue	us-gaap:Revenues	\$2.1M	2023-01-31	2024-05-01	10-K	0001213900-24-037996
13	gross profit	us-gaap:GrossProfit	\$554,310	2022-01-31	2023-04-26	10-K	0001213900-23-032682
14	revenue	us-gaap:Revenues	\$1.4M	2022-01-31	2023-04-26	10-K	0001213900-23-032682
15	current assets	us-gaap:AssetsCurrent	\$5.0M	2026-01-31	2026-04-29	10-K	0001213900-26-049399
16	current liabilities	us-gaap:LiabilitiesCurrent	\$784,281	2026-01-31	2026-04-29	10-K	0001213900-26-049399
17	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-\$46.7M	2026-01-31	2026-04-29	10-K	0001213900-26-049399
18	operating income	us-gaap:OperatingIncomeLoss	-\$8.3M	2026-01-31	2026-04-29	10-K	0001213900-26-049399
19	book equity	us-gaap:StockholdersEquity	\$6.7M	2026-01-31	2026-04-29	10-K	0001213900-26-049399
20	liabilities	us-gaap:Liabilities	\$868,447	2026-01-31	2026-04-29	10-K	0001213900-26-049399
21	operating income	us-gaap:OperatingIncomeLoss	-\$4.9M	2024-01-31	2025-04-28	10-K	0001213900-25-036201
22	interest expense	us-gaap:InterestExpense	\$75,815	2024-01-31	2024-05-01	10-K	0001213900-24-037996
23	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$5,324	2026-01-31	2026-04-29	10-K	0001213900-26-049399
24	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$4.6M	2025-01-31	2026-04-29	10-K	0001213900-26-049399
25	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$92,043	2025-01-31	2026-04-29	10-K	0001213900-26-049399
26	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$3.5M	2024-01-31	2025-04-28	10-K	0001213900-25-036201
27	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$51,761	2024-01-31	2025-04-28	10-K	0001213900-25-036201
28	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$3.0M	2023-01-31	2024-05-01	10-K	0001213900-24-037996
29	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$79,304	2023-01-31	2024-05-01	10-K	0001213900-24-037996
30	assets	us-gaap:Assets	\$7.5M	2024-01-31	2025-04-28	10-K	0001213900-25-036201
31	assets	us-gaap:Assets	\$9.5M	2023-01-31	2024-05-01	10-K	0001213900-24-037996